In addition, Chen et al. have demonstrated that mutations in CDK12, TP53 (tumor suppressor p53) and PIK3CA are the most frequent in 107 HER2-positive breast cancer patients [58]. This evidence concerns the gene ERBB2 and breast carcinoma.